Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A histologically established diagnosis of multiple myeloma with evidence of relapse or refractory disease.~* Must have a detectable serum or urine M-Protein by protein electrophoresis that is at least 500 mg/dL (serum) or 1 gm/24 hours (urine), respectively, or serum free light chain level \>100 mg/l for the involved free light chain.~* Must have received at least one (1) prior line of systemic treatment that has included either lenalidomide or thalidomide.~* Must be willing to provide correlative blood samples.~Exclusion Criteria:~* Must not have received an excessive cumulative dose of anthracycline~* No ≥ grade 2 peripheral neuropathy.~* No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy.~* No autologous stem cell transplant within 6 months prior to registration for protocol therapy~* No prior radiation therapy to \> 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.~* No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.~* No known central nervous system involvement by myeloma.~* No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social climate that in the opinion of the investigator would limit compliance with study requirements.~* No patients known to be positive for HIV, or active Hepatitis A, B, or C.~* No major surgery within 30 days prior to registration for protocol therapy. Placement of a venous access device within 30 days prior to registration for protocol therapy is allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.

Based on this trial design, predict the completion outcome and termination type (if applicable).